<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02914795</url>
  </required_header>
  <id_info>
    <org_study_id>27-290ex14/15</org_study_id>
    <nct_id>NCT02914795</nct_id>
  </id_info>
  <brief_title>Platelet Function in Resuscitated Patients</brief_title>
  <official_title>Platelet Function in Resuscitated Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approx. 65% of resuscitated patients at the intensive care unit for internal medicine are due&#xD;
      to myocardial infarction. Almost all patients are initially diagnosed and treated in the cath&#xD;
      lab. Therapy usually consists of one or more stent implantations. After implantation of a&#xD;
      coronary stent, dual platelet inhibition is necessary for 12 months. Insufficient platelet&#xD;
      inhibition causes an pronounced increase in risk of stent thrombosis. Therefore, knowledge of&#xD;
      the individual platelet function is valuable.&#xD;
&#xD;
      Several factors potentially promote a delayed or reduced mode of action of platelet function&#xD;
      inhibitors in resuscitated patients:&#xD;
&#xD;
        1. oral administration is impossible and medication needs to be administered via a gastric&#xD;
           line.&#xD;
&#xD;
        2. gastric absorption is delayed after resuscitation&#xD;
&#xD;
        3. according to current guidelines patients are treated with therapeutic hypothermia.&#xD;
           Including the time of rewarming cooling period is ~48h&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients after successful resuscitation associated to a myocardial infarction will be&#xD;
      included into the study the morning after the index event. Patients get dual platelet&#xD;
      inhibition at the discretion of the interventionist. Patients are treated with therapeutic&#xD;
      hypothermia according to the local Standard operating procedure for 24h and rewarming is&#xD;
      performed within an additional 20h. Platelet function is measured every morning and Aspirin&#xD;
      mediated as well as P2Y12 (purinergic G protein-coupled receptors-12)-inhibition mediated&#xD;
      platelet function inhibition is recorded. All relevant clinical data including APACHE (Acute&#xD;
      Physiology and Chronic Health Evaluation) and SOFA ( Sequential Organ Failure Assessment&#xD;
      score) scores are collected.&#xD;
&#xD;
      The degree of platelet inhibition over time (7 days) and differences between the three drugs&#xD;
      tested will be evaluated by optical aggregometry and by using the commercial VerifyNow test&#xD;
      system.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Inhibition Measured With Optical Aggregometry</measure>
    <time_frame>day 3</time_frame>
    <description>Median (Inter-Quartile Range) Collagen AUC values on Day 3 measured with optical aggregometry The more light signal is detected, the better thrombocyte function is.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cumulative Clinical Endpoint of Death and Stent Thrombosis</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">99</enrollment>
  <condition>Acute ST Segment Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>non-resuscitated myocardial infarction</arm_group_label>
    <description>diagnostic analysis of platelet function of a matched historical cohort of the ATLANTIS-ACS trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>resuscitated myocardial infarction</arm_group_label>
    <description>diagnostic analysis of platelet function of the patient cohort included according to the inclusion criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic analysis of platelet function</intervention_name>
    <description>analysis of platelet aggregation using optical measurements as well as the commercial VerifyNow technique</description>
    <arm_group_label>non-resuscitated myocardial infarction</arm_group_label>
    <arm_group_label>resuscitated myocardial infarction</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients surviving the first night after resuscitation due to myocardial infarction&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Myocardial infarction&#xD;
&#xD;
          -  dual platelet inhibition&#xD;
&#xD;
          -  resuscitation&#xD;
&#xD;
          -  therapeutic hypothermia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk von Lewinski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>McNicol A, Israels SJ. Platelets and anti-platelet therapy. J Pharmacol Sci. 2003 Dec;93(4):381-96. Review.</citation>
    <PMID>14737006</PMID>
  </reference>
  <reference>
    <citation>Tendera M, Wojakowski W. Role of antiplatelet drugs in the prevention of cardiovascular events. Thromb Res. 2003 Jun 15;110(5-6):355-9. Review.</citation>
    <PMID>14592562</PMID>
  </reference>
  <reference>
    <citation>Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003 Jun 17;107(23):2908-13. Epub 2003 Jun 9.</citation>
    <PMID>12796140</PMID>
  </reference>
  <reference>
    <citation>Puri KS, Suresh KR, Gogtay NJ, Thatte UM. Declaration of Helsinki, 2008: implications for stakeholders in research. J Postgrad Med. 2009 Apr-Jun;55(2):131-4. doi: 10.4103/0022-3859.52846.</citation>
    <PMID>19550060</PMID>
  </reference>
  <reference>
    <citation>Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008 Nov 4;52(19):1557-63. doi: 10.1016/j.jacc.2008.07.055.</citation>
    <PMID>19007592</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 12, 2016</study_first_submitted>
  <study_first_submitted_qc>September 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2016</study_first_posted>
  <results_first_submitted>March 21, 2018</results_first_submitted>
  <results_first_submitted_qc>December 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 3, 2020</results_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Non-resuscitated Myocardial Infarction</title>
          <description>diagnostic analysis of platelet function of a matched historical cohort of the ATLANTIS-ACS trial&#xD;
diagnostic analysis of platelet function: analysis of platelet aggregation using optical measurements as well as the commercial VerifyNow technique</description>
        </group>
        <group group_id="P2">
          <title>Resuscitated Myocardial Infarction</title>
          <description>diagnostic analysis of platelet function of the patient cohort included according to the inclusion criteria&#xD;
diagnostic analysis of platelet function: analysis of platelet aggregation using optical measurements as well as the commercial VerifyNow technique</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Non-resuscitated Myocardial Infarction</title>
          <description>diagnostic analysis of platelet function of a matched historical cohort of the ATLANTIS-ACS trial&#xD;
diagnostic analysis of platelet function: analysis of platelet aggregation using optical measurements as well as the commercial VerifyNow technique</description>
        </group>
        <group group_id="B2">
          <title>Resuscitated Myocardial Infarction</title>
          <description>diagnostic analysis of platelet function of the patient cohort included according to the inclusion criteria&#xD;
diagnostic analysis of platelet function: analysis of platelet aggregation using optical measurements as well as the commercial VerifyNow technique</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="77"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.3" lower_limit="59.3" upper_limit="72.7"/>
                    <measurement group_id="B2" value="65" lower_limit="50" upper_limit="75.8"/>
                    <measurement group_id="B3" value="64.5" lower_limit="60.5" upper_limit="72.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Collagen AUC day 1</title>
          <description>Aspirin reactivity was monitored by inducing platelet aggregation with 2 Âµg/mL collagen and 0.5 mmol L-1 arachidonic acid (AA, Chronolog Corp., Havertown, PA, USA), respectively.&#xD;
First measurement was on day one and thus represents baseline.</description>
          <units>AU*min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="219" lower_limit="80.5" upper_limit="334.5"/>
                    <measurement group_id="B2" value="69.5" lower_limit="46.7" upper_limit="195.6"/>
                    <measurement group_id="B3" value="185.8" lower_limit="77" upper_limit="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Platelet Inhibition Measured With Optical Aggregometry</title>
        <description>Median (Inter-Quartile Range) Collagen AUC values on Day 3 measured with optical aggregometry The more light signal is detected, the better thrombocyte function is.</description>
        <time_frame>day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-resuscitated Myocardial Infarction</title>
            <description>diagnostic analysis of platelet function of a matched historical cohort of the ATLANTIS-ACS trial&#xD;
diagnostic analysis of platelet function: analysis of platelet aggregation using optical measurements</description>
          </group>
          <group group_id="O2">
            <title>Resuscitated Myocardial Infarction</title>
            <description>diagnostic analysis of platelet function of the patient cohort included according to the inclusion criteria&#xD;
diagnostic analysis of platelet function: analysis of platelet aggregation using optical measurements</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Inhibition Measured With Optical Aggregometry</title>
          <description>Median (Inter-Quartile Range) Collagen AUC values on Day 3 measured with optical aggregometry The more light signal is detected, the better thrombocyte function is.</description>
          <units>AU*min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109" lower_limit="73" upper_limit="182"/>
                    <measurement group_id="O2" value="253.8" lower_limit="122.7" upper_limit="352.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cumulative Clinical Endpoint of Death and Stent Thrombosis</title>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-resuscitated Myocardial Infarction</title>
            <description>diagnostic analysis of platelet function of a matched historical cohort of the ATLANTIS-ACS trial&#xD;
diagnostic analysis of platelet function: analysis of platelet aggregation using optical measurements as well as the commercial VerifyNow technique</description>
          </group>
          <group group_id="O2">
            <title>Resuscitated Myocardial Infarction</title>
            <description>diagnostic analysis of platelet function of the patient cohort included according to the inclusion criteria&#xD;
diagnostic analysis of platelet function: analysis of platelet aggregation using optical measurements as well as the commercial VerifyNow technique</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cumulative Clinical Endpoint of Death and Stent Thrombosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Resuscitated MI</title>
          <description>Death within the Observation period of 7 days; n=3</description>
        </group>
        <group group_id="E2">
          <title>Non Resuscitated MI</title>
          <description>Death within the Observation period of 7 days; n=0</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>High on aspirin platelet reactivity</sub_title>
                <description>High on aspirin platele reactivity defined as collagene AUC &gt; 500</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Assoc. Prof. Dr. Dirk von Lewinski</name_or_title>
      <organization>Medical University of Grazt</organization>
      <phone>+43 316 385 ext 80684</phone>
      <email>dirk.von-lewinski@medunigraz.at</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

